Drug Trial Radar · NCT06730386
A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 24, 2025
Primary completion
Feb 26, 2028
Study completion Aug 30, 2028
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.
Conditions
- Solid Cancer
Interventions
AK138D1Drug
Enrolled subjects will receive intravenous infusion (IV) of AK138D1 according to the dosing regimen specified in their cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AEsTime frame: Up to approximately 2 years
- Dose-limiting toxicity (DLT)Time frame: Up to approximately 2 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Blacktown Hospital-Blacktwon Cancer and Haematology Centre
Blacktown, New South Wales, Australia · Not yet recruiting
Macquarie University
North Ryde, New South Wales, Australia · Not yet recruiting
ICON Cancer Centre South Brisbane
South Brisbane, Queensland, Australia · Recruiting
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.